SOLBEC PHARMACEUTICALS CLINICAL TRIAL PATIENTS ELECT TO CONTINUE...

SOLBEC PHARMACEUTICALS CLINICAL TRIAL PATIENTS ELECT TO CONTINUE ANTI-CANCER DRUG
Summary:
• Size reduction in previously resistant tumours.
• Patients elect to complete a further cycle of treatment with SBP002.
• Principal Investigator describes findings as “very encouraging”.

Perth, Australia. 9 September 2004. Solbec Pharmaceuticals Ltd (ASX:SBP) today
announced that its anti-cancer drug SBP002 was effective in reducing tumour size in
some patients involved in a Phase I trial, and have requested to continue taking the drug.
Analysis of new data from the first group of patients to undergo treatment in the Phase I
trial was encouraging with some of the patients showing reduction in their tumours, and a
number of patients with advanced cancer had elected to continue treatment. In these
cases, the patients had not responded to other treatments.
The trial, which is designed to determine the safe dose that would allow the company to
move into Phase II clinical trials, has now enrolled 13 patients. A review of the data
generated to date has identified what is believed to be a safe dose for this next stage. The
company and Investigator, Professor Michael Millward, are continuing to work on the
drug to identify the most appropriate treatment protocol for the phase II trials.
Professor Millward, the Principal Investigator, said: “Although it is too early to determine
the full effect of this new drug, the results that we have seen in the early patients have
been very encouraging. A number of patients have shown a positive response to the drug
and elected to continue therapy for a further three months.”